Template usage is responsible for the preferential acquisition of the K65R reverse transcriptase mutation in subtype C variants of human immunodeficiency virus type 1.
about
Impact of human immunodeficiency virus type-1 sequence diversity on antiretroviral therapy outcomesStructural Basis for the Role of the K65R Mutation in HIV-1 Reverse Transcriptase Polymerization, Excision Antagonism, and Tenofovir ResistanceNucleic acid template and the risk of a PCR-Induced HIV-1 drug resistance mutationK65R in subtype C HIV-1 isolates from patients failing on a first-line regimen including d4T or AZT: comparison of Sanger and UDP sequencing dataHIV-1 drug resistance and resistance testing.HIV-1 Genetic Variability and Clinical ImplicationsComparative biochemical analysis of recombinant reverse transcriptase enzymes of HIV-1 subtype B and subtype C.The K65R mutation in HIV-1 reverse transcriptase: genetic barriers, resistance profile and clinical implications.HIV-1 reverse transcriptase and antiviral drug resistance. Part 2.A template-dependent dislocation mechanism potentiates K65R reverse transcriptase mutation development in subtype C variants of HIV-1The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy.Subtype-associated differences in HIV-1 reverse transcription affect the viral replication.HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial.HIV-1 antiretroviral resistance: scientific principles and clinical applicationsDrug resistance in non-B subtype HIV-1: impact of HIV-1 reverse transcriptase inhibitors.Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C.Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes.Characterizing the emergence and persistence of drug resistant mutations in HIV-1 subtype C infections using 454 ultra deep pyrosequencingDetection of low-level K65R variants in nucleoside reverse transcriptase inhibitor-naive chronic and acute HIV-1 subtype C infections.Silent mutations at codons 65 and 66 in reverse transcriptase alleviate indel formation and restore fitness in subtype B HIV-1 containing D67N and K70R drug resistance mutations.Role of HIV Subtype Diversity in the Development of Resistance to Antiviral Drugs.HIV Genetic Diversity and Drug Resistance.A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses.Subtype-specific analysis of the K65R substitution in HIV-1 that confers hypersusceptibility to a novel nucleotide-competing reverse transcriptase inhibitor.The Impact of HIV Genetic Polymorphisms and Subtype Differences on the Occurrence of Resistance to Antiretroviral Drugs.Comparative analysis of drug resistance among B and the most prevalent non-B HIV type 1 subtypes (C, F, and CRF02_AG) in Italy.Intersubtype differences in the effect of a rare p24 gag mutation on HIV-1 replicative fitness.Emerging antiretroviral drug resistance in sub-Saharan Africa: novel affordable technologies are needed to provide resistance testing for individual and public health benefits.Low rates of nucleoside reverse transcriptase inhibitor resistance in a well-monitored cohort in South Africa on antiretroviral therapyNucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudineHigh rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimenBasis for early and preferential selection of the E138K mutation in HIV-1 reverse transcriptase.Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996-2008)Targeting of the purine biosynthesis host cell pathway enhances the activity of tenofovir against sensitive and drug-resistant HIV-1HIV-1 Drug Resistance by Ultra-Deep Sequencing Following Short Course Zidovudine, Single-Dose Nevirapine, and Single-Dose Tenofovir with Emtricitabine for Prevention of Mother-to-Child Transmission.Low-abundance resistant mutations in HIV-1 subtype C antiretroviral therapy-naive individuals as revealed by pyrosequencing.Clinical significance of HIV reverse-transcriptase inhibitor-resistance mutations.HIV-1 mutational pathways under multidrug therapy.Effects of the K65R and K65R/M184V reverse transcriptase mutations in subtype C HIV on enzyme function and drug resistance.Prevalence and dynamics of the K65R drug resistance mutation in HIV-1-infected infants exposed to maternal therapy with lamivudine, zidovudine and either nevirapine or nelfinavir in breast milk.
P2860
Q26851997-B7993219-A3BE-4F9B-8656-4BE4E58BC5A3Q27657718-C9D5F177-80FF-4312-952B-221A7CBEC57AQ28474274-C1F90DF5-12E7-498C-B667-4C652BCBE349Q28483758-A5FEC008-786E-4F5B-A074-BBB152151092Q30245693-136BEDE6-5317-4715-883B-4F3BAE7A9CE0Q30352010-59494E80-800F-4B6C-96F3-47B70A92FDA4Q30394627-A9F0A6DE-1906-4E8E-A41F-9C3E1B949863Q33681279-217272E0-474B-4C4D-9034-A0E0489135F8Q33900459-24F39B29-8089-407A-9B38-0832F486A133Q33927293-DE4F79E0-BC6A-40D9-A48F-C24740C9BFBCQ33959260-27E7EE2B-CA99-45F8-B73F-728BD0BC9D9AQ34243467-FE6B1FF7-F57B-42D3-8A68-C2A91F9B9680Q34249966-C90CD531-8F8B-470E-8453-D2656DC1A463Q34280466-17E46462-F47C-4829-90AD-A2E8543DBF5BQ34303603-DADB6EFF-08BD-4A66-959D-EB683BE966CCQ34489239-9DE702F4-0101-4A29-9CF6-CA8EC29687AEQ34529310-E3E835E9-CBA5-4E20-A18D-CF55DF1BE02BQ34567556-F31AFEFA-905F-4E81-9166-358CBF5B4AB5Q34764036-DEE57814-B28E-4C0A-B765-779C1381C3E0Q35237036-A50DD7F6-57BF-4442-91AA-6228C68B546CQ35260403-70CA64F1-5D06-4529-81E3-522537B718B0Q35260590-AA28F246-F93A-448A-AFE7-714EBC2E80DCQ35370552-EC039788-B272-45E7-BB9D-95A76B1EA0CEQ35607740-0E9CCC0C-1F0F-499E-AC47-60303D3E999DQ36077418-B59B1137-107F-44AF-B8AC-86FFDB9BDF55Q36250342-8AC41154-E30E-42B1-81A6-2B05414FFC44Q36414578-056F8D89-BF14-4FA5-AC5F-78AEC50CDC2FQ36669337-610C0562-A16F-4CC1-9BE1-7A79095A87EDQ36693481-FC0634C2-096D-4F7E-AD0C-BD26C9E1FC50Q36852626-65863774-A2FC-46CA-8D18-463F38FC077BQ37133188-EA3EE15F-5F40-4766-AA7E-116C1AE63388Q37263786-8FCEBA9A-E558-4B6C-9FA3-3E08F7CE6B0AQ37268341-01E2A536-4594-40D3-8E5B-420757402D5EQ37332192-FEA580EA-1E18-48DB-BEC4-63B792002E4DQ37519808-02C488E8-D2B3-480A-A0C5-76A55AD0B613Q37734688-8C9A2F08-B9BA-4FD6-BAD9-F276E1D549B2Q37859395-A5C49022-CAC3-498C-8557-8FE1109BE0E6Q38264403-D8B4238C-2592-44D3-B9B2-0E1166381BE9Q38356685-AE39CE41-B90B-4190-A326-086B17D88943Q38898319-6EF62F8B-D251-465D-AEDF-68A54234AA96
P2860
Template usage is responsible for the preferential acquisition of the K65R reverse transcriptase mutation in subtype C variants of human immunodeficiency virus type 1.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Template usage is responsible ...... immunodeficiency virus type 1.
@en
type
label
Template usage is responsible ...... immunodeficiency virus type 1.
@en
prefLabel
Template usage is responsible ...... immunodeficiency virus type 1.
@en
P2093
P2860
P356
P1433
P1476
Template usage is responsible ...... immunodeficiency virus type 1.
@en
P2093
Bluma G Brenner
Cédric F Invernizzi
Daniela Moisi
Dimitrios Coutsinos
Hongtao Xu
Mark A Wainberg
Maureen Oliveira
P2860
P304
P356
10.1128/JVI.01349-08
P407
P577
2008-12-10T00:00:00Z